PM
PMDI.US Psychemedics Corporation
- Market cap
- USD 15.2M
- P/E
- -
- P/B
- 2.97x
- ROE
- -36.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is PMDI.US undervalued?
Graham numberThe Graham number of Psychemedics Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Psychemedics Corporation fundamental analysis
No fundamental analysis for Psychemedics Corporation yet.
Psychemedics Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Psychemedics Corporation
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hy…
Full company profilePsychemedics Corporation financial statements
Psychemedics Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 21.4M | 24.9M | 25.2M | 22.1M | 19.7M |
| Gross Profit | 4.89M | 10.3M | 9.29M | 8.41M | 7.10M |
| Operating Income | -6.07M | 209K | -1.08M | -2.92M | -1.89M |
| EBITDA | - | 3.90M | 2.23M | -751K | 191K |
| Net Income | -3.86M | -665K | -1.08M | -4.15M | -1.86M |
| EPS | -0.70 | -0.12 | -0.19 | -0.72 | -0.30 |
| Balance Sheet | |||||
| Total Assets | 24.0M | 21.6M | 18.7M | 12.3M | 8.32M |
| Total Liabilities | 11.5M | 9.31M | 7.96M | 5.65M | 3.19M |
| Shareholders' Equity | 12.5M | 12.2M | 10.8M | 6.67M | 5.13M |
| Cash & Short-term Investments | 2.83M | 1.99M | 4.75M | 1.96M | 1.42M |
| Cash Flow | |||||
| Operating Cash Flow | -4.08M | 414K | 4.89M | -1.48M | 929K |
| Capital Expenditure | 991K | 182K | 187K | 157K | 87.0K |
| Free Cash Flow | -5.07M | 232K | 4.70M | -1.64M | 842K |
| Ratios | |||||
| ROE | -30.8% | -5.4% | -10.1% | -62.3% | -36.3% |
| ROA | -16.1% | -3.1% | -5.8% | -33.7% | -22.4% |
| Net Profit Margin | -18.1% | -2.7% | -4.3% | -18.8% | -9.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Psychemedics Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 24, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | USD 799K | 0.14 | - |
| 2022 | USD 1.19M | 0.21 | - |
| 2021 | USD 279K | 0.05 | - |
| 2020 | USD 993K | 0.18 | - |
| 2013 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4976:5000 on Dec 4, 2024.
Who owns Psychemedics Corporation
- Insiders 51.02%
- Institutions 0.00%
- Public & others 48.98%
- Shares outstanding 6.11M
- Free float 3.00M
Psychemedics Corporation company profile
- Company name
- Psychemedics Corporation
- Ticker
- PMDI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 101
- Fiscal year end
- December
- Address
- 5220 Spring Valley Road, Dallas, TX, United States, 75254
- Phone
- 800 628 8073
- Website
- psychemedics.com
About Psychemedics Corporation
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising aka K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Dallas, Texas.
Psychemedics Corporation management
5- Mr. Brian HullingerPresident, CEO & Director · born 1968
- Ms. Daniella MehalikVP of Finance & Treasurer · born 1991
- Ms. Shannon ShoemakerVP & Chief Revenue Officer · born 1987
- Dr. Werner A. Baumgartner Ph.D.Founder
- Mr. Patrick J. Kinney Jr.Secretary